Lion's mane (Hericium erinaceus) is an edible mushroom traditionally used in East Asian medicine that has gained attention for its potential neurocognitive benefits. The fungus contains two classes of bioactive compounds—hericenes (from the fruiting body) and erinacines (from the mycelium)—that stimulate nerve growth factor (NGF) synthesis in astrocytes.
The primary therapeutic mechanism of lion's mane involves stimulation of nerve growth factor (NGF) synthesis. The bioactive compounds work through the following pathway:
The stimulation of NGF supports:
Some studies show downstream BDNF upregulation, but this appears to be secondary to NGF signaling rather than a direct effect[4]. The evidence for direct BDNF stimulation is weaker than for NGF.
Erinacines (particularly erinacine A) have demonstrated ability to cross the blood-brain barrier in animal models[3:1], which is critical for CNS therapeutic efficacy.
| Attribute | Details |
|---|---|
| Study | Improving effects of Hericium erinaceus on mild cognitive impairment: a double-blind placebo-controlled clinical trial |
| PMID | 18844328 |
| Design | Double-blind, parallel-group, placebo-controlled RCT |
| Sample | 30 participants with mild cognitive impairment (15 per group) |
| Dosage | 4 × 250 mg tablets of 96% lion's mane dry powder, 3× daily (total 3 g/day) |
| Duration | 16 weeks active + 4 weeks off-treatment observation |
| Outcome | Revised Hasegawa Dementia Scale (HDS-R) |
| Results | Significant improvement in HDS-R scores at weeks 8, 12, and 16 vs. placebo; scores declined 4 weeks after discontinuation |
This study provides the most direct evidence for cognitive benefits in MCI, though the sample size is small (n=30)[5].
| Attribute | Details |
|---|---|
| Study | Improvement of cognitive functions by oral intake of Hericium erinaceus |
| PMID | 31413233 |
| Design | Randomized, double-blind, placebo-controlled |
| Duration | 12 weeks |
| Dosage | Fruiting body extract (specific dose not reported in abstract) |
| Outcome | Mini-Mental State Examination (MMSE), Benton visual retention test, Standard verbal paired-associate learning test |
| Results | Significant improvement in MMSE scores; prevented cognitive deterioration |
This study extends the evidence to healthy adults with age-related cognitive decline[6].
| Attribute | Details |
|---|---|
| Study | Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia |
| PMID | 32581767 |
| Design | Double-blind, placebo-controlled, randomized parallel-group |
| Duration | 49 weeks |
| Dosage | Three 350 mg capsules/day of erinacine A-enriched mycelia (5 mg/g erinacine A) |
| Outcome | CASI, MMSE, IADL, biomarkers, neuroimaging |
| Results | Significant MMSE improvement vs. placebo; better IADL scores; enhanced contrast sensitivity; only 4 dropouts due to mild adverse events (abdominal discomfort, nausea, skin rash) |
This study specifically used erinacine A-enriched mycelium, addressing the formulation issue discussed below[7].
| Attribute | Details |
|---|---|
| Study | The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults |
| PMID | 38004235 |
| Design | Double-blind, parallel groups, pilot study |
| Sample | Young adults |
| Results | Shows promise for improving cognitive function and mood |
The bioactive compound profile differs dramatically between parts:
| Component | Source | Key Compounds | NGF Activity |
|---|---|---|---|
| Fruiting body | Mushroom caps | Hericenones | Moderate |
| Mycelium | Cultured mycelium | Erinacines A-I | Potent (erinacine A is strongest) |
| Mycelium on grain | Commercial supplements | Often mostly grain, minimal erinacines | Weak |
Critical issue: Many commercial "lion's mane" supplements are mycelium grown on grain, which contains negligible erinacines. The fruiting body contains hericenones but not erinacines. True dual extracts or dedicated mycelium products are required for maximal NGF-stimulating activity.
| Brand | Type | Erinacines | Notes |
|---|---|---|---|
| Host Defense | Mycelium extract | Yes | Independent testing confirms erinacines |
| Nootropics Depot | Dual extract | Yes | Fruiting body + mycelium |
| Real Mushrooms | Fruiting body | No (hericenes only) | Hericenones, no erinacines |
| Criterion | Rating |
|---|---|
| Mechanism plausibility | High (NGF stimulation documented) |
| Clinical evidence strength | Moderate (small RCTs, mostly MCI) |
| Safety | Excellent |
| Relevance to CBS/PSP | Speculative but safe to try |
| Overall | Consider — low-risk supportive therapy |
Lion's mane demonstrates an excellent safety profile across clinical trials:
Ma et al. Erinacine A: A potent NGF inducer (2010). J Nat Prod. 2010. ↩︎
Kenmoku et al. Erinacine A biosynthesis (2017). Biosci Biotechnol Biochem. 2017. ↩︎
Chong et al. Therapeutic Potential of Hericium erinaceus for Depressive Disorder (2019). Int J Mol Sci. 2019. ↩︎ ↩︎
Mori et al. Improving effects of Hericium erinaceus on mild cognitive impairment (2009). Phytother Res. 2009. ↩︎
Saitsu et al. Improvement of cognitive functions by oral intake of Hericium erinaceus (2019). Biomed Res. 2019. ↩︎
Li et al. Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia (2020). Front Aging Neurosci. 2020. ↩︎
Docherty et al. Acute and Chronic Effects of Lion's Mane Mushroom Supplementation (2023). Nutrients. 2023. ↩︎ ↩︎